X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RTX-003 is a targeted anti-CD25 monoclonal antibody that binds CD25 without blocking IL-2 on the high-affinity IL-2 receptor alpha on T regulatory (T reg) cells, and designed to induce T reg cell death, thus supporting tumor immunity.
Lead Product(s): RTX-003
Therapeutic Area: Oncology Product Name: RTX-003
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: iBio
Deal Size: $6.0 million Upfront Cash: $1.0 million
Deal Type: Acquisition September 21, 2022
Details:
The company will present discovery and pre-clinical data from their lead program RTX-003, a CD25 targeted monoclonal antibody for selective depletion of regulatory T cells (Tregs) in the tumor microenvironment (TME) at the AACR Virtual Conference.
Lead Product(s): RTX-003
Therapeutic Area: Oncology Product Name: RTX-003
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
